Pasithea Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Pasithea Therapeutics Corp. (KTTA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-13.90-15.96-13.94-2.17-0.06
Depreciation & Amortization0.650.650.010.000.00
Stock Based Compensation0.770.590.841.220.00
Change in Working Capital-1.521.570.850.110.00
Change in Accounts Payable0.001.070.750.440.01
Change in Other Working Capital-1.520.500.36-0.33-0.01
Other Operating Activities0.850.400.36-2.330.00
Net Cash from Operating Activities-13.92-13.43-13.69-3.17-0.06
Investing Activities
Capital Expenditures0.00-0.03-0.11-0.020.00
Acquisitions0.000.00-2.190.000.00
Other Investing Activities0.000.32-0.630.000.00
Net Cash from Investing Activities0.000.40-2.93-0.020.00
Financing Activities
Debt Repayment0.00-0.390.000.000.00
Common Stock Issued4.520.000.0057.240.42
Common Stock Repurchased0.00-3.73-3.210.000.00
Other Financing Activities-0.480.00-3.21-1.310.00
Net Cash from Financing Activities4.52-3.73-3.2155.930.42
Summary
Effect of Forex Changes on Cash0.000.000.01-0.010.00
Net Change in Cash-9.41-16.76-19.8252.720.37
Cash at Beginning of Period16.3333.0952.900.240.00
Cash at End of Period6.9216.3333.0952.970.00
Free Cash Flow-13.92-13.46-13.80-3.20-0.06